Polyclonal antibody stimulator(Aphton Corp.)(Polyclonal antibody stimulator(Aphton Corp.)) - 药物靶点：GAST_在研适应症：胰腺癌，胃癌_专利_临床

概要

基本信息

药物类型

治疗性疫苗、结合疫苗

别名

Anti-gastrin 17 immunogen、Antigastrin 17、Gastrimmune

+ [9]

靶点

GAST

作用方式

抑制剂、刺激剂

作用机制

GAST抑制剂(促胃泌素17抑制剂)、免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

Cancer Advances, Inc.

权益机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

16

项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的临床试验

NCT00020787

/ Completed临床3期IIT

An Open Label, Sequential Multi-Center Multi Dose Study Of G17T Immunogen In Combination With Cisplatin (CDDP) And 5-Fluorouracil (5-FU) In Subjects With Metastatic Or Locally Recurrent Gastric Or Gastroesophageal Cancer Previously Untreated With Chemotherapy For Advanced Disease (Stage IV)

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy and chemotherapy in treating patients who have metastatic or locally recurrent stomach cancer or esophageal cancer.

开始日期2001-07-01

申办/合作机构

Jonsson Comprehensive Cancer Center

NCT02118077

/ Completed临床3期

A Prospective, Randomized, Double-blind, Placebo-controlled, Group Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer.

Compare the effect of G17DT with that of placebo on the survival of subjects with advanced pancreatic cancer.

开始日期2001-04-01

申办/合作机构

Cancer Advances, Inc.

NCT02118064

/ Completed临床2期

A Multinational, Multicenter, Open-label, Single-arm, Phase II Study of G17DT Immunogen in Combination With Irinotecan in Metastatic Colorectal Carcinoma Refractory to Previous Irinotecan-based Chemotherapy.

This study was designed to evaluate the ability for G17DT to slow or arrest tumor growth in patients with refractory colon cancer who had been previously treated with an Irinotecan-based chemotherapy.

开始日期2001-03-01

申办/合作机构

Cancer Advances, Inc.

100 项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的临床结果

登录后查看更多信息

100 项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的转化医学

登录后查看更多信息

100 项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的专利（医药）

登录后查看更多信息

2,638

项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的文献（医药）

2025-12-01·Food chemistry. Molecular sciences

Effects of dietary prickly ash seeds supplementation on muscle development and volatile compounds of Hu sheep

Article

作者: Wu, Yi ; Ma, Youji ; Wang, Chunhui ; Li, Qiao ; Liu, Zilong ; Ma, Xueyi

Prickly ash seeds (PAS), a nutrient-rich by-product, show potential as a sustainable feed for Hu sheep. The current study aims to explore the effects of dietary supplementation with PAS on muscle development and volatile compounds of Hu sheep through multi-omics analysis. The increased muscle fiber diameter and cross-sectional area was associated with dietary supplementation with PAS compared with the CK group (P < 0.05). Transcriptome analysis showed that ACTC1, SERPINA3, COX2, MYBPH, FMOD, and KLHL34 were key differentially expressed genes (DEGs) involved in muscle growth and development, and played a role through oxidative phosphorylation, TCA cycle, fatty acid metabolism, and tryptophan metabolism. The combined analysis of transcriptome and volatile metabolomics showed that LEP, ADCY1, TMEM54, COX2, PCK1, and CPT1A may play an important regulatory role in the production of volatile compounds such as cetene, dodecanal, 2,6-dodecadien-1-al, palmitoleic acid, dodecanoic acid, ethyl ester by participating in lipid metabolism. In summary, PAS demonstrates promise for Hu sheep production, enhancing muscle development and influencing muscle flavor by modulating fatty acid metabolism-related genes.

2025-12-01·FOOD CHEMISTRY

Pyrrolizidine alkaloids in honey: occurrence and profile analysis in Japan

Article

作者: Yamazaki, Kazuo ; Yamaguchi, Nobuyasu ; Nakamura, Misako ; Nakatani, Tadashi

In this study, we investigated the amounts of 15 types of pyrrolizidine alkaloids (PAs) and 12 corresponding N-oxides (PANOs) in honey samples purchased from retail stores, supermarkets, and internet stores in Japan using LC-MS/MS with a new sample preparation method. Among the 129 honey samples analysed, 93.8 % contained detectable levels above the limit of quantification, with concentrations ranging from 0.012 to 69.8 μg kg^-1, and mean and median values of 3.92 and 0.49 μg kg^-1, respectively. Among the 27 targeted PAs/PANOs, 17 were detected, with intermedine and lycopsamine exhibiting high detection rates. No significant differences were observed in contamination levels between Japanese and imported honey. However, PA profiles varied between Japanese and imported products. The margin of exposure values for PAs/PANOs exceeded 10,000, indicating low public health concern. Japanese honey profiles were classified into three groups, with Group 1 (Boraginaceae and Eupatorium species) accounting for over 50 % of the samples.

2025-12-01·ARCHIVES OF MICROBIOLOGY

In-vitro analysis of biofilm formation and synergistic antibiotic-phage therapy for amoxicillin-resistant Escherichia coli

Article

作者: Singh, Ayu ; Vishwakarma, Ranjeet Kumar ; Kumar, Ashish ; Yadav, Bhupendra Singh ; Nath, Gopal ; Gautam, Priyanka ; Sahu, Minakshi

Biofilm formation by Escherichia coli (E. coli) significantly enhances bacterial resistance to antibiotics, complicating treatment, particularly in amoxicillin-resistant strains. Bacteriophage therapy demonstrates potential in treating biofilm-related infections, and the combination of phages and antibiotics (phage-antibiotic synergy, PAS) further enhances efficacy. This is the first study to evaluate PAS using penicillin-class antibiotics against multidrug-resistant (MDR) Gram-negative bacteria, E. coli. E. coli-specific lytic bacteriophages were isolated and characterized. PAS was evaluated in both planktonic and biofilm forms using sub-inhibitory concentrations of AMC. The viability of biofilm and planktonic forms was assessed not only by colony counts but also by flow cytometry. Moreover, morphological alterations were evaluated by scanning electron microscopy (SEM), and genomic alterations by PAS were analyzed through whole genome fingerprinting using ERIC PCR. In biofilm and planktonic form, phage first achieved effective bacterial killing after 24 h, when 10⁶ PFU/mL was supplemented with amoxicillin clavulanic acid (AMC) combination after 7 h for optimal PAS killing. PAS treatment significantly reduced biofilm viability compared to phage therapy only, while AMC was not effective at all. SEM revealed disrupted cell walls, detachment of flagella, and rupture of bacterial cells, as well as changes in morphology and biofilm matrix in combination therapy. Phage-first treatment with ɸA3 followed by AMC after 7 h effectively eradicates multidrug-resistant E. coli, causing genomic changes that restore antibiotic sensitivity at subinhibitory doses, potentially addressing antimicrobial resistance. In PAS, a cocktail of phages may be advised to avoid the emergence of phage mutant strains.

1

项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的新闻（医药）

2023-02-28

·BioSpace

Cancer Advances, Inc. Announces Issuance of New U.S. Patent - February 28, 2023

DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S. Patent and Trademark Office has issued new patent No. 11,583,576, enhancing the Company’s intellectual property position for lead asset Polyclonal Antibody Stimulator (PAS) vaccine. The new patent titled “Compositions and Methods for Inducing Humoral and Cellular Immunities against Tumors and Cancer” covers a method for treating and/or preventing and/or inhibiting development of a tumor and/or a cancer associated with gastrin signaling in a subject. Gastrin mediated tumors include, but are not limited to, gastrointestinal cancers. The novel IP further covers methods for treatment of GI cancer by administering PAS followed by an immune checkpoint inhibitor. A related claim covers reduction in fibrosis associated with pancreatic cancer via the administration of this combination. “After more than six years of research, we are excited to have this patent issued. We have known that PAS can induce the development of antibodies to Gastrin, bringing Gastrin levels down and increasing survival times by 50% in GI clinical trials. With our research now demonstrating that PAS is able to alter the tumor microenvironment, it opens the door to many new opportunities to improve current treatment for GI cancer patients,” commented Lynda Sutton, President of Cancer Advances. The issued patent adds to the over one hundred granted global patents for PAS. Cancer Advances plans to seek approval for PAS in the treatment of gastric and pancreatic cancers. About Cancer Advances, Inc. Cancer Advances Inc. (Durham, NC) is a biotechnology company focused on impacting human health and preventing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team with over one hundred and twenty years of combined experience in drug development and commercialization experience. About Polyclonal Antibody Stimulator (PAS) Polyclonal Antibody Stimulator (PAS) vaccine is an immunomodulator potentially applicable in multiple cancer types including gastric, pancreatic, and colorectal. The vaccine is a peptide-conjugate that includes an N-terminal epitope of human gastrin-17 (G17) linked to carrier diphtheria toxoid. PAS has been studied in multiple clinical trials, in over 1,500 human subjects, and has demonstrated an excellent safety and tolerability profile. Cancer Advances exclusively owns PAS and is funding and managing all aspects of the PAS gastrin vaccine program. Contact Cancer Advances, Inc. E-mail: jwingen@canceradvances.com

疫苗免疫疗法

100 项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB04914

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胃癌	临床3期	美国	Cancer Advances, Inc.	2009-01-19
胰腺腺癌	临床3期	-	Cancer Advances, Inc.	2000-08-14
胰腺癌	临床3期	-	Aphton Corp.	-
食管癌	临床2期	-	Cancer Advances, Inc.	2000-08-01
胃食管交界处恶性肿瘤	临床2期	-	Cancer Advances, Inc.	2000-08-01
胃腺癌	临床2期	-	Cancer Advances, Inc.	1998-09-01
转移性结直肠癌	临床2期	-	Cancer Advances, Inc.	1994-05-01
大肠腺癌	临床2期	英国	Cancer Advances, Inc.	1993-10-01
晚期结直肠腺癌	临床2期	英国	Cancer Advances, Inc.	1993-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2006	临床3期	-	-	Gemcitabine + G17DT	鑰憲衊築餘齋獵選夢願(蓋襯壓選齋積憲構淵獵) = 淵遞蓋製廠憲簾觸襯壓襯艱醖壓網鹽遞觸夢艱 (觸遞淵齋襯壓鹽顧獵醖 )	-	2006-06-20
				Gemcitabine alone (placebo)	鑰憲衊築餘齋獵選夢願(蓋襯壓選齋積憲構淵獵) = 憲壓製網窪蓋鏇襯選鑰襯艱醖壓網鹽遞觸夢艱 (觸遞淵齋襯壓鹽顧獵醖 )
ASCO2004	N/A	晚期胰腺腺癌	154	G17DT	艱簾壓醖衊製選醖網醖(積襯顧廠餘鹹膚衊蓋鏇) = 壓遞齋蓋鏇鏇艱餘簾衊壓鹽糧窪衊糧淵簾膚糧 (膚選淵糧獵鏇簾觸範鑰 )	积极	2004-07-15
				Placebo	艱簾壓醖衊製選醖網醖(積襯顧廠餘鹹膚衊蓋鏇) = 襯鹽鑰鏇網製築糧鑰積壓鹽糧窪衊糧淵簾膚糧 (膚選淵糧獵鏇簾觸範鑰 )